<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25397551</article-id><article-id pub-id-type="pmc">4225388</article-id><article-id pub-id-type="publisher-id">19807</article-id><article-id pub-id-type="doi">10.7448/IAS.17.4.19807</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Sessions &#x02013; Abstract P275</subject></subj-group></article-categories><title-group><article-title>Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reeves</surname><given-names>Iain</given-names></name><xref ref-type="aff" rid="AF0001_19807">1</xref></contrib><contrib contrib-type="author"><name><surname>Fisher</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="AF0002_19807">2</xref></contrib><contrib contrib-type="author"><name><surname>Kegg</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="AF0003_19807">3</xref></contrib><contrib contrib-type="author"><name><surname>Arribas</surname><given-names>Jose</given-names></name><xref ref-type="aff" rid="AF0004_19807">4</xref></contrib><contrib contrib-type="author"><name><surname>Dau</surname><given-names>Lauren</given-names></name><xref ref-type="aff" rid="AF0005_19807">5</xref></contrib><contrib contrib-type="author"><name><surname>Garner</surname><given-names>Will</given-names></name><xref ref-type="aff" rid="AF0006_19807">6</xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Ivan</given-names></name><xref ref-type="aff" rid="AF0005_19807">5</xref></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Thai</given-names></name><xref ref-type="aff" rid="AF0005_19807">5</xref></contrib></contrib-group><aff id="AF0001_19807"><label>1</label>Homerton Sexual Health Services, Homerton University Hospital, London, UK</aff><aff id="AF0002_19807"><label>2</label>Brighton and Sussex University Hospital NHS Trust, Department of HIV, Brighton, UK</aff><aff id="AF0003_19807"><label>3</label>The Trafalgar Clinic, Queen Elizabeth Hospital, London, UK</aff><aff id="AF0004_19807"><label>4</label>Consulta de Medicina Interna II, Hospital Universitario La Paz, Madrid, Spain</aff><aff id="AF0005_19807"><label>5</label>HIV Medical Affairs, Gilead Sciences, Foster City, USA</aff><aff id="AF0006_19807"><label>6</label>Department of Biostatistics, Gilead Sciences, Foster City, USA</aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>4Suppl 3</issue><elocation-id content-type="doi">19807</elocation-id><permissions><copyright-statement>&#x000a9; 2014 Reeves I et al; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1_19807"><title>Introduction</title><p>Cobicistat, a component of stribild (STB), is known to inhibit renal creatinine secretion. A detailed analysis of the renal safety profile of STB in two Phase 3b switch studies of virologically-suppressed individuals on stable therapy: STRATEGY(S)-PI (STB vs a RTV-boosted protease inhibitor [PI] with emtricitabine and tenofovir DF [FTC/TDF]); and STRATEGY(S)-NNRTI (STB versus a non-nucleoside reverse transcriptase inhibitor [NNRTI] with FTC/TDF) is herein described.</p></sec><sec id="st2_19807"><title>Materials and Methods</title><p>Baseline eGFR &#x02265;70 mL/min was an inclusion criterion. The renal safety profile of STB was examined by baseline eGFR through week 48 (i.e., changes in eGFR, renal tubular laboratory abnormalities, investigator-reported renal adverse events leading to discontinuation and unreported subclinical proximal renal tubulopathy [PRT]). Subclinical PRT was defined as a confirmed serum-creatinine increase &#x02265;0.4 mg/dL and two or three markers of renal tubular dysfunction (hypophosphatemia, normoglycemic glycosuria, proteinuria) occurring at the same visit at least once and with no alternative etiologies.</p></sec><sec id="st3_19807"><title>Results</title><p>In S-PI, 433 subjects (STB 293; PI 140) and in S-NNRTI, 434 subjects (STB 291; NNRTI 143) were randomized and treated. Most (&#x0003e;85%) STB subjects had a baseline eGFR &#x02265;90 mL/min. STB subjects with baseline eGFR &#x0003c;90 mL/min had smaller declines in eGFR compared to those with baseline eGFR &#x02265;90 mL/min and similar occurrences of renal tubular laboratory abnormalities (<xref ref-type="table" rid="T0001_19807">Table 1</xref>). Rate of renal adverse events leading to study drug discontinuation were similar for the STB group (one PRT in a subject with baseline tubular laboratory abnormalities consistent with underlying PRT and one isolated increase in serum creatinine) and PI group (one isolated decrease in eGFR); none in the NNRTI group. The case of PRT improved after study drug discontinuation. There were no cases of unreported subclinical PRT in any group.</p></sec><sec id="st4_19807"><title>Conclusions</title><p>In this virologically suppressed patient population, the renal safety of STB did not differ by baseline eGFR. The renal discontinuation rate was low in the STB group, similar to the RTV-boosted PI group, and consistent with published historical rates.</p></sec></abstract></article-meta></front><body><table-wrap id="T0001_19807" position="float"><label>Table 1</label><caption><p>Changes in eGFR at week 48 and tubular laboratory abnormalities by baseline eGFR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">S-PI Study Arm</th><th align="center" rowspan="1" colspan="1">STB</th><th align="center" rowspan="1" colspan="1">STB</th><th align="center" rowspan="1" colspan="1">PI+RTV</th><th align="center" rowspan="1" colspan="1">PI+RTV</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Baseline eGFR (mL/min) category</td><td align="center" rowspan="1" colspan="1">&#x0003c;90 (n=40)</td><td align="center" rowspan="1" colspan="1">&#x02265;90 (n=253)</td><td align="center" rowspan="1" colspan="1">&#x0003c;90 (n=27)</td><td align="center" rowspan="1" colspan="1">&#x02265;90 (n=113)</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes from baseline at week 48: eGFR (mL/min), median (IQR)</td><td align="center" rowspan="1" colspan="1">&#x02212;3.8 (&#x02212;8.1 to 1.2)</td><td align="center" rowspan="1" colspan="1">&#x02212;8.9 (&#x02212;16.9 to 0.4)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.2 (&#x02212;4.5 to 5.0)</td><td align="center" rowspan="1" colspan="1">0.5 (&#x02212;9.1 to 7.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypophosphatemia<xref ref-type="table-fn" rid="TF0001_19807">*</xref></td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.4% (1)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Normoglycemic glycosuria<xref ref-type="table-fn" rid="TF0001_19807">*</xref></td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Proteinuria<xref ref-type="table-fn" rid="TF0001_19807">*</xref></td><td align="center" rowspan="1" colspan="1">5.0% (2)</td><td align="center" rowspan="1" colspan="1">9.5% (24)</td><td align="center" rowspan="1" colspan="1">11.1% (3)</td><td align="center" rowspan="1" colspan="1">7.1% (8)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>S-NNRTI Study Arm</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>STB</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>STB</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>PI+RTV</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>PI+RTV</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline eGFR (mL/min) category</td><td align="center" rowspan="1" colspan="1">&#x0003c;90 (n=43)</td><td align="center" rowspan="1" colspan="1">&#x02265;90 (n=248)</td><td align="center" rowspan="1" colspan="1">&#x0003c;90 (n=20)</td><td align="center" rowspan="1" colspan="1">&#x02265;90 (n=123)</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes from baseline at week 48: eGFR (mL/min), median (IQR)</td><td align="center" rowspan="1" colspan="1">&#x02212;8.0 (&#x02212;11.6 to 0.9)</td><td align="center" rowspan="1" colspan="1">&#x02212;12.6 (&#x02212;21.2 to &#x02212;6.3)</td><td align="center" rowspan="1" colspan="1">7.4 (1.9 to 14.4)</td><td align="center" rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;10.9 to 5.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypophosphatemia<xref ref-type="table-fn" rid="TF0001_19807">*</xref></td><td align="center" rowspan="1" colspan="1">4.7% (2)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1.6% (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Normoglycemic glycosuria<xref ref-type="table-fn" rid="TF0001_19807">*</xref></td><td align="center" rowspan="1" colspan="1">2.3% (1)</td><td align="center" rowspan="1" colspan="1">1.2% (3)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Proteinuria<xref ref-type="table-fn" rid="TF0001_19807">*</xref></td><td align="center" rowspan="1" colspan="1">9.3% (4)</td><td align="center" rowspan="1" colspan="1">6.9% (17)</td><td align="center" rowspan="1" colspan="1">10% (2)</td><td align="center" rowspan="1" colspan="1">4.9% (6)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TF0001_19807"><label>*</label><p>&#x02265;1-grade increase from baseline observed at two consecutive post-baseline visits (within 30 days after last dose date).</p></fn></table-wrap-foot></table-wrap></body></article>